在化學(xué)與生物學(xué)的接口上發(fā)表具有突出意義和及時(shí)性的研究通訊，并邀請(qǐng)簡(jiǎn)明的評(píng)論文章。該雜志發(fā)表了關(guān)于藥物化學(xué)、化學(xué)生物學(xué)和藥物發(fā)現(xiàn)與設(shè)計(jì)的實(shí)驗(yàn)結(jié)果的報(bào)告，強(qiáng)調(diào)了這些領(lǐng)域新的和新出現(xiàn)的進(jìn)展和概念。這本雜志的目的是促進(jìn)人們更好地了解生命過程的分子水平、活生物體以及它們與化學(xué)試劑的相互作用。該雜志仍然是在新化學(xué)實(shí)體進(jìn)入臨床試驗(yàn)之前首次出版的主要論壇。該期刊歡迎發(fā)表以下論文：已建立或新的疾病靶點(diǎn)的藥物化學(xué)和相關(guān)生物學(xué)（包括靶點(diǎn)識(shí)別和確認(rèn)）；發(fā)現(xiàn)、設(shè)計(jì)或優(yōu)化有效新化合物或生物制劑的報(bào)告；利用體外和體內(nèi)模型分析和討論與藥物設(shè)計(jì)和作用相關(guān)的結(jié)構(gòu)-活性關(guān)系和藥理學(xué)問題，包括在與實(shí)驗(yàn)數(shù)據(jù)密切相關(guān)時(shí)使用計(jì)算技術(shù)；“一流”新型治療化合物的報(bào)道；顯著提高生物機(jī)制知識(shí)的化學(xué)生物學(xué)或生物有機(jī)/生物無機(jī)化學(xué)；以化學(xué)為基礎(chǔ)，對(duì)醫(yī)學(xué)或生物學(xué)有重大影響的方法學(xué)進(jìn)展；病理生理疾病狀態(tài)生物治療的制備與檢測(cè)；特定治療靶向材料的開發(fā)。有關(guān)植物化學(xué)、理論分子動(dòng)力學(xué)和專門的計(jì)算論文的手稿超出范圍。所有手稿將由獨(dú)立專家在編輯初步評(píng)估后進(jìn)行嚴(yán)格的同行評(píng)審。請(qǐng)注意，BMCL不適合直接報(bào)告增量預(yù)付款。最重要的是，無論工作的確切領(lǐng)域是什么，合理的基礎(chǔ)和合理的基本假設(shè)的提出都是特別重要的。

publishes research communications of outstanding significance and timeliness on topics at the interface of chemistry and biology, together with invited concise review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The journal continues to be a major forum for the first publication of new chemical entities prior to them entering clinical trials.The Journal welcomes papers on:the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targetsthe reporting of the discovery, design or optimization of potent new compounds or biological agentsthe analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental datathe reporting of "first-in-class" new therapeutic compoundsthe chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanismmethodological advances that are chemistry-based and which significantly impact on medicine or biologythe preparation and examination of biotherapeutics for the treatment of pathophysiological disease statesthe development of materials for specific therapeutic targetingManuscripts on phytochemistry, theoretical molecular dynamics and exclusively computational papers are out of scope. All manuscripts will be rigorously peer-reviewed by independent experts following an initial assessment by the Editors. Please note that BMCL is not suitable for straightforward reports of incremental advances. Above all the presentation of a rational basis and a sound underlying hypothesis for the work is of particular importance, whatever its exact field.